CliffBio
small molecule

RYZUMVI

PHENTOLAMINE MESYLATE

Loss of exclusivityOctober 2039latest FDA-listed patent expiry
CompanyFAMYGEN LIFE SCIENCES INC

Drug detail

Brand nameRYZUMVI
Active ingredientPHENTOLAMINE MESYLATE
StrengthEQ 0.75% BASE
Dosage formSOLUTION
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalSeptember 2023
Marketing statusRX

Listed patents

PatentExpiresType
12576067October 2039use U-3804
12576066October 2039use U-3804
11400077October 2039use U-3804
12201615October 2039use U-3804
12201616October 2039use U-3804
11090261January 2034product
10278918January 2034product
10772829January 2034product
12721810January 2034product
12734126January 2034use U-4604
12350366January 2034product
11844858January 2034product
9795560January 2034product

Regulatory exclusivity

CodeExpires
NPSeptember 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.